Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€79.36
11.08.22
€110.00
11.08.23
22.37%
12.08.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
buy
Cellectis Nom.

Start price
Target price
Perf. (%)
€3.52
07.08.22
€3.80
07.08.23
-52.13%
08.08.23

Could be worthwhile Investment >10% per year
buy
Abivax S.A.

Start price
Target price
Perf. (%)
€9.10
04.08.22
-
04.08.23
81.32%
05.08.23

Could be very worthwhile Investment >20% year
buy
EssilorLuxottica SA

Start price
Target price
Perf. (%)
€157.25
29.07.22
€200.00
29.07.23
14.87%
30.07.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Valneva SE

Start price
Target price
Perf. (%)
€9.82
21.07.22
-
21.07.23
-30.16%
22.07.23

Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
buy
EssilorLuxottica SA

Start price
Target price
Perf. (%)
€146.15
15.07.22
€175.00
15.07.23
21.16%
16.07.23

buy
Poxel S.A.

Start price
Target price
Perf. (%)
€2.49
20.08.22
-
20.08.23
-75.54%
07.06.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€10.23
09.08.22
€14.00
09.08.23
-46.91%
30.05.23

Small cyclical dependencies
Below average Marketposition
Few uniques
buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€85.88
28.10.22
-
28.10.23
16.27%
18.05.23

Risky Investment
Abivax S.A.

Start price
Target price
Perf. (%)
€8.30
02.09.22
€5.00
31.12.24
85.30%
08.05.23

Could be very worthwhile Investment >20% year
Sanofi S.A.

Start price
Target price
Perf. (%)
€79.94
11.08.22
€63.00
30.09.24
26.47%
08.05.23

Could be worthwhile Investment >10% per year
buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€88.01
01.11.22
€100.00
31.12.24
13.11%
05.05.23

Could be worthwhile Investment >10% per year
Spineway

Start price
Target price
Perf. (%)
€2.20
12.12.22
-
12.12.23
-61.36%
24.04.23

Risky Investment
Growths slower than the competition
Novacyt S.A.

Start price
Target price
Perf. (%)
€1.06
05.09.22
-
05.09.23
-46.97%
24.04.23

Probably not worthwhile Investment
buy
Gensight Biologics SA

Start price
Target price
Perf. (%)
€2.34
07.04.22
-
07.04.23
-1.02%
08.04.23

Could be worthwhile Investment >10% per year
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.17
08.02.23
-
08.02.24
-9.35%
03.04.23

Could be very worthwhile Investment >20% year
buy
Ipsen S.A.

Start price
Target price
Perf. (%)
€112.45
25.03.22
-
25.03.23
-6.98%
27.03.23

Gensight Biologics SA

Start price
Target price
Perf. (%)
€2.97
07.03.22
-
07.03.23
-19.53%
08.03.23

Risky Investment
Innate Pharma

Start price
Target price
Perf. (%)
€2.51
07.03.22
-
07.03.23
21.39%
08.03.23

Probably not worthwhile Investment
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.58
20.02.23
-
20.02.24
-1.16%
05.03.23

Could be very worthwhile Investment >20% year
buy
Sartorius Stedim Biotech S.A.

Start price
Target price
Perf. (%)
€328.00
20.02.22
€400.00
20.02.23
1.01%
21.02.23

Could be worthwhile Investment >10% per year
Orpea Nom.

Start price
Target price
Perf. (%)
€2.87
05.02.23
-
05.02.24
-10.07%
18.02.23

Could be very worthwhile Investment >20% year
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€2.36
07.02.23
€4.00
07.02.24
9.32%
18.02.23

Could be very worthwhile Investment >20% year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Innate Pharma

Start price
Target price
Perf. (%)
€3.24
10.02.22
€3.80
10.02.23
-4.81%
11.02.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.03
05.02.22
€20.00
05.02.23
-57.41%
06.02.23

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Good culture
Could be very worthwhile Investment >20% year